Toshio Shimizu

机构：Kansai Medical University, Wakayama Medical University, National Cancer Centre Japan, National Cancer Center Hospital East, Tokyo National Hospital · ORCID：0000-0001-6632-0638

发表论文 767 篇 · 总被引 9197 次 · h-index 43

代表论文

• 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases (2025 · Annals of Oncology · 被引 2)
• Abstract P4-04-28: PF-07248144, a first-in-class KAT6 inhibitor, in patients with HR+ HER2− metastatic breast cancer: Updated results from phase 1 dose expansion study (2025 · Clinical Cancer Research · 被引 2)
• Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes (2025 · International Journal of Clinical Oncology · 被引 1)
• Data from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Table 2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Figure S5 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)